IMRX
Immuneering Corporation
NASDAQ · Healthcare · Biotechnology · US
$4.82
−4.37%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | 317.0K |
| Cost of Revenue | 793.2K | 698.9K | — | — | 158.1K |
| Gross Profit | (793.2K) | (698.9K) | — | — | 158.8K |
| Operating Expenses | |||||
| R&D Expense | 10.7B | 42.0M | 48.0M | 41.6M | 36.3M |
| SG&A Expense | 4.7B | 17.3M | 16.1M | 16.8M | 15.6M |
| General & Admin Expense | 4.7B | 17.3M | 16.1M | 16.8M | 15.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (15.3B) | (669.6K) | 29.0K | 28.9K | 29.6K |
| Total Operating Expenses | 62.7M | 58.7M | 64.1M | 58.4M | 51.9M |
| Cost and Expenses | 63.5M | 59.4M | 64.1M | 58.4M | 52.1M |
| Operating Income (EBIT) | (63.5M) | (59.4M) | (64.1M) | (58.4M) | (51.7M) |
| Non-Operating | |||||
| Interest Income | (410.7M) | 3.0M | 2.6M | 3.6M | 1.0M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | (410.7M) | 3.0M | 2.6M | 3.6M | 1.0M |
| Other Non-Op Income/Expense | 6.2M | 3.4M | 3.0M | 4.9M | 1.2M |
| Non-Operating Income (excl Interest) | (1.3M) | (3.4M) | 254.00 | 398.00 | 471.00 |
| EBT (Pre-Tax Income) | (57.3M) | (56.0M) | (61.0M) | (53.5M) | (50.5M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (57.3M) | (56.0M) | (61.0M) | (53.5M) | (50.5M) |
| Earnings from Cont. Ops | (57.3M) | (56.0M) | (61.0M) | (53.5M) | (50.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (57.3M) | (56.0M) | (61.0M) | (53.5M) | (50.5M) |
| Per Share | |||||
| Basic EPS | ($1.04) | ($1.27) | ($2.04) | ($1.88) | ($1.87) |
| Diluted EPS | ($1.04) | ($1.27) | ($2.04) | ($1.88) | ($1.87) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.01 |
| Shares | |||||
| Basic Shares Outstanding | 64.7M | 44.0M | 30.0M | 28.4M | 26.4M |
| Diluted Shares Outstanding | 64.7M | 44.0M | 30.0M | 28.4M | 26.4M |
| Profitability Metrics | |||||
| EBITDA | (61.4M) | (55.3M) | (63.7M) | (58.1M) | (51.5M) |
| D&A | 779.4K | 698.9K | 385.1K | 352.1K | 277.3K |
| EBIT | (62.2M) | (56.0M) | (64.1M) | (58.4M) | (51.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026